Generic placeholder image

Current Respiratory Medicine Reviews

Editor-in-Chief

ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

The Use of Interferons in Respiratory Diseases

Author(s): Ori-Michael J. Benhamou, Miriam Jacobs, Jonathan Drew, Shahar Geva, Maor Waldman and Or Kalchiem-Dekel

Volume 9 , Issue 5 , 2013

Page: [318 - 322] Pages: 5

DOI: 10.2174/1573398X10666140520004706

Price: $65

Abstract

Interferons (IFNs) are a subclass of lymphocyte-released cytokines that interfere with intracellular viral replication. These drugs are classified into three groups: IFN type 1 (IFN-α, IFN-β, and IFN-ω), IFN type 2 (IFN-γ), and IFN type 3 (IFN-λ). Despite numerous trials, IFN therapy has yet to conclusively demonstrate superiority in the treatment of various pulmonary diseases. In addition to the FDA-approved and ongoing investigational uses for IFN therapy, there is a debate regarding the appropriate dosage of these agents. A retrospective literature review is moving experts towards low-dose therapies in nearly every application of IFN therapy. It is speculated that known and unknown toxicity may limit the beneficial effects of IFN therapy.

Keywords: Asthma, idiopathic pulmonary fibrosis, influenza, interferon.

Graphical Abstract

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy